Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings report shows strong financial metrics with revenue, operating income, and EPS all increasing significantly. The company's strategic focus on expanding its sales force and product awareness has paid off, particularly in the homecare segment. The approval of a stock repurchase plan and actual buybacks signal confidence in future prospects. While SG&A expenses have risen, the overall financial health remains robust. The Q&A session highlighted growth opportunities and strategic initiatives. Despite minor concerns about rep productivity, the strong financial performance and strategic initiatives suggest a positive stock price movement.
Revenue $18.9 million, a 16.3% year-over-year increase. Growth driven by strong performance in the core homecare business (18.4% increase) and distributor channel (12.1% increase). Decline in hospital channel revenue (9.4%) due to prioritization of shipments to home patients and timing of capital orders.
Operating Income $3.6 million, a 42.4% year-over-year increase. Growth attributed to increased revenue and gross profit.
Earnings Per Share (EPS) $0.32 per diluted share, compared to $0.22 per diluted share in the prior year, reflecting a 40.3% increase. Driven by higher revenue and operating income.
Gross Profit $14.8 million, 78.4% of net revenues, up from $12.6 million or 77.7% of net revenues. Increase due to higher overall revenue and net revenues per device.
SG&A Expenses $10.8 million, a 10% year-over-year increase. Increase due to higher salaries and incentive compensation from increased sales headcount and overall compensation costs.
Net Income $2.8 million, a 40.3% year-over-year increase. Growth driven by increased revenue and operating income.
Cash Balance $13.8 million, reflecting a decrease of $1.5 million over six months due to $3.2 million positive operating cash flow offset by $3.8 million in share repurchases.
SmartVest Airway Clearance Solution: Achieved 13th consecutive quarter of year-over-year revenue and profit growth. Promoted as part of a 3-pronged treatment paradigm for bronchiectasis, focusing on airway clearance, infection treatment, and inflammation reduction.
Smart Order e-Prescribe solution: Improved prescription submission process, replacing outdated fax-based methods. Over 1/3 of orders now come through this platform, enhancing clinic workflow and patient experience.
Bronchiectasis market: Targeting approximately 923,000 diagnosed patients in the U.S., with only 16% currently benefiting from high-frequency chest wall oscillation therapy. Potential to address over 4 million undiagnosed cases.
Payer contracts: Executed 25 new contracts in the first half of fiscal year, adding 2.9 million covered lives to the existing 270 million.
Sales team expansion: Increased direct sales representatives to 58, with plans to grow to 61 by fiscal year-end. Annualized homecare revenue per sales representative exceeded target range.
Manufacturing optimization: Redesigned manufacturing layout to improve production efficiency and support future growth. Maintained U.S.-based operations with mid-70% gross margins.
Triple-down on bronchiectasis campaign: Launched a 3-pronged treatment paradigm to address bronchiectasis, focusing on airway clearance, infection treatment, and inflammation reduction. Participated in trade shows and educational events to raise awareness.
CRM system implementation: Enhanced field sales productivity, market insights, and communication with fulfillment teams, leading to improved sales productivity and patient experience.
Hospital Channel Revenue Decline: The hospital channel experienced a 9.4% year-over-year decline in revenue due to strategic prioritization of shipments to high-demand home patients and the unpredictable timing of capital orders. This could impact overall revenue growth if the hospital demand does not rebound as anticipated.
Tariff Exposure: While the company benefits from U.S.-centric operations, there is a potential risk from tariffs affecting domestic suppliers' upstream supply chains, which could increase costs or disrupt supply.
Underserved Market Challenges: Despite the large market opportunity in the bronchiectasis segment, only 16% of diagnosed patients are currently benefiting from high-frequency chest wall oscillation therapy. Additionally, 58% of qualifying patients are not prescribed the therapy despite meeting clinical criteria, indicating challenges in market penetration and awareness.
Supply Chain and Manufacturing Risks: Although the company has optimized its manufacturing layout, any disruptions in the supply chain or inefficiencies in production could impact its ability to meet demand and maintain gross margins.
Increased SG&A Expenses: Selling, general, and administrative expenses increased by 10%, primarily due to higher salaries and incentive compensation. This could pressure operating margins if revenue growth does not keep pace with rising costs.
Bronchiectasis Market Opportunity: Electromed aims to address the underserved bronchiectasis market, with approximately 923,000 diagnosed patients in the U.S., of which only 16% currently benefit from high-frequency chest wall oscillation therapy. The company sees potential to help nearly 800,000 diagnosed patients and over 4 million undiagnosed individuals.
Triple-Down on Bronchiectasis Campaign: Launched in 2025, this campaign promotes a 3-pronged treatment paradigm: 1) Clear Airways First with SmartVest, 2) Treat infections with antibiotics, and 3) Reduce inflammation. This approach aims to break the cycle of chronic infection and inflammation in bronchiectasis patients.
Sales Force Expansion: Electromed plans to increase its direct sales representatives from 58 to 61 by the end of fiscal year 2026 to enhance market reach and clinician engagement.
Smart Order e-Prescribe Solution: The company is implementing a digital prescription platform to replace fax-based processes, improving order efficiency and patient experience. Over one-third of orders in Q2 were processed through this platform.
Manufacturing Optimization: Electromed completed a manufacturing layout redesign to improve production efficiency and support future growth.
Revenue Growth: Electromed expects to continue delivering double-digit top-line growth in the coming quarters and full fiscal year 2026.
Operating Leverage: The company anticipates expanded operating leverage, supported by increased revenue and gross profit.
Hospital Channel Recovery: Electromed expects hospital demand to rebound in the coming quarters after a decline in Q2 due to strategic prioritization of homecare shipments.
Sales Representative Productivity: The company targets annualized homecare revenue per sales representative in the range of $1 million to $1.1 million, with Q2 performance exceeding this range at $1.2 million per representative.
Stock Repurchase Authorization: The Board approved a $10 million stock repurchase authorization in Q1, reflecting confidence in Electromed's future and commitment to delivering shareholder value.
Share Repurchases: Electromed repurchased $3.8 million of its common stock during the 6 months ended December 31, 2025.
The earnings report shows strong financial metrics with revenue, operating income, and EPS all increasing significantly. The company's strategic focus on expanding its sales force and product awareness has paid off, particularly in the homecare segment. The approval of a stock repurchase plan and actual buybacks signal confidence in future prospects. While SG&A expenses have risen, the overall financial health remains robust. The Q&A session highlighted growth opportunities and strategic initiatives. Despite minor concerns about rep productivity, the strong financial performance and strategic initiatives suggest a positive stock price movement.
The earnings call highlights strong financial performance with a 15% revenue increase and 38% rise in operating income. The strategic expansion of sales territories and focus on the bronchiectasis market are promising. The $10 million stock repurchase program indicates confidence in the company's value. However, economic uncertainties and unclear management responses about hospital sales create slight concerns. Overall, the sentiment is positive due to strong growth metrics, strategic initiatives, and shareholder returns.
The earnings call highlights strong financial performance, with significant revenue and net income growth, improved gross margins, and efficient cash management. Positive developments include successful sales team expansion, effective CRM implementation, and promising hospital channel growth. The Q&A section reveals favorable analyst sentiment and market expansion opportunities, despite some management vagueness. The company's proactive strategies, including share repurchases and manufacturing optimization, support a positive outlook. Overall, the combination of strong earnings, optimistic guidance, and strategic initiatives suggests a positive stock price movement over the next two weeks.
Electromed reported strong financial performance with record revenues, a significant increase in net income, and high gross margins. The share repurchase program and positive cash flow are favorable for shareholder returns. Despite concerns about tariffs and competitive pressures, the company maintains a strong cash position and plans to expand its sales team. The Q&A revealed some vagueness in management's responses, but overall sentiment remains positive due to optimistic guidance and strategic initiatives like the CRM system and marketing campaign.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.